{"id":33060,"date":"2025-05-09T12:11:27","date_gmt":"2025-05-09T04:11:27","guid":{"rendered":"https:\/\/flcube.com\/?p=33060"},"modified":"2025-05-09T12:11:28","modified_gmt":"2025-05-09T04:11:28","slug":"pfizers-zavicefta-approved-by-chinas-nmpa-for-severe-infections-in-all-ages","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33060","title":{"rendered":"Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages"},"content":{"rendered":"\n

US-based pharmaceutical giant Pfizer (NYSE: PFE<\/a>) announced that it has received market approval from China’s National Medical Products Administration (NMPA) for its avibactam sodium + ceftazidime product, branded as Zavicefta. The drug is indicated for the treatment of complex intra-abdominal infections (cIAI) caused by gram-negative bacteria, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). It is also approved for infections with limited treatment options in children of all ages, including newborns.<\/p>\n\n\n\n

Drug Overview and Previous Approvals<\/strong>
Zavicefta was first approved in China in May 2019 for treating cIAI, HAP, and ventilator-associated pneumonia, as well as infections caused by specific gram-negative bacteria such as Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Proteus mirabilis, and Pseudomonas aeruginosa in adult patients with limited therapeutic options. In October 2022, the drug received further approval in China for treating children aged three months and older with cIAI.<\/p>\n\n\n\n

Acquisition and Development History<\/strong>
Zavicefta was co-developed by AstraZeneca and Allergan’s unit Forest Laboratories. Pfizer acquired the drug through a small-molecule antibiotics business deal with AstraZeneca in December 2016, obtaining exclusive development, marketing, and commercialization rights globally, excluding the US and Canada.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China’s…<\/p>\n","protected":false},"author":1,"featured_media":33061,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[863,15],"class_list":["post-33060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nyse-pfe","tag-product-approvals"],"yoast_head":"\nPfizer's Zavicefta Approved by China's NMPA for Severe Infections in All Ages - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China's National Medical Products Administration (NMPA) for its avibactam sodium + ceftazidime product, branded as Zavicefta. The drug is indicated for the treatment of complex intra-abdominal infections (cIAI) caused by gram-negative bacteria, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). It is also approved for infections with limited treatment options in children of all ages, including newborns.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33060\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer's Zavicefta Approved by China's NMPA for Severe Infections in All Ages\" \/>\n<meta property=\"og:description\" content=\"US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China's National Medical Products Administration (NMPA) for its avibactam sodium + ceftazidime product, branded as Zavicefta. The drug is indicated for the treatment of complex intra-abdominal infections (cIAI) caused by gram-negative bacteria, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). It is also approved for infections with limited treatment options in children of all ages, including newborns.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33060\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-09T04:11:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-09T04:11:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages\",\"datePublished\":\"2025-05-09T04:11:27+00:00\",\"dateModified\":\"2025-05-09T04:11:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0902.webp\",\"keywords\":[\"NYSE: PFE\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33060#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33060\",\"name\":\"Pfizer's Zavicefta Approved by China's NMPA for Severe Infections in All Ages - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0902.webp\",\"datePublished\":\"2025-05-09T04:11:27+00:00\",\"dateModified\":\"2025-05-09T04:11:28+00:00\",\"description\":\"US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China's National Medical Products Administration (NMPA) for its avibactam sodium + ceftazidime product, branded as Zavicefta. The drug is indicated for the treatment of complex intra-abdominal infections (cIAI) caused by gram-negative bacteria, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). It is also approved for infections with limited treatment options in children of all ages, including newborns.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33060\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0902.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer's Zavicefta Approved by China's NMPA for Severe Infections in All Ages\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33060#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's Zavicefta Approved by China's NMPA for Severe Infections in All Ages - Insight, China's Pharmaceutical Industry","description":"US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China's National Medical Products Administration (NMPA) for its avibactam sodium + ceftazidime product, branded as Zavicefta. The drug is indicated for the treatment of complex intra-abdominal infections (cIAI) caused by gram-negative bacteria, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). It is also approved for infections with limited treatment options in children of all ages, including newborns.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33060","og_locale":"en_US","og_type":"article","og_title":"Pfizer's Zavicefta Approved by China's NMPA for Severe Infections in All Ages","og_description":"US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China's National Medical Products Administration (NMPA) for its avibactam sodium + ceftazidime product, branded as Zavicefta. The drug is indicated for the treatment of complex intra-abdominal infections (cIAI) caused by gram-negative bacteria, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). It is also approved for infections with limited treatment options in children of all ages, including newborns.","og_url":"https:\/\/flcube.com\/?p=33060","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-09T04:11:27+00:00","article_modified_time":"2025-05-09T04:11:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33060#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33060"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages","datePublished":"2025-05-09T04:11:27+00:00","dateModified":"2025-05-09T04:11:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33060"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33060#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0902.webp","keywords":["NYSE: PFE","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33060#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33060","url":"https:\/\/flcube.com\/?p=33060","name":"Pfizer's Zavicefta Approved by China's NMPA for Severe Infections in All Ages - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33060#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33060#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0902.webp","datePublished":"2025-05-09T04:11:27+00:00","dateModified":"2025-05-09T04:11:28+00:00","description":"US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China's National Medical Products Administration (NMPA) for its avibactam sodium + ceftazidime product, branded as Zavicefta. The drug is indicated for the treatment of complex intra-abdominal infections (cIAI) caused by gram-negative bacteria, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). It is also approved for infections with limited treatment options in children of all ages, including newborns.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33060#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33060"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33060#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0902.webp","width":1080,"height":608,"caption":"Pfizer's Zavicefta Approved by China's NMPA for Severe Infections in All Ages"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33060#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33060"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33060\/revisions"}],"predecessor-version":[{"id":33062,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33060\/revisions\/33062"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33061"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}